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Neuregulins (NRGs) comprise a large family of growth factors that stimulate ERBB receptor tyrosine kinases.
NRGs and their receptors, ERBBs, have been identified as susceptibility genes for diseases such as schizo-
phrenia (SZ) and bipolar disorder. Recent studies have revealed complex Nrg/Erbb signaling networks that
regulate the assembly of neural circuitry, myelination, neurotransmission, and synaptic plasticity. Evidence
indicates there is an optimal level of NRG/ERBB signaling in the brain and deviation from it impairs brain
functions. NRGs/ERBBs and downstream signaling pathways may provide therapeutic targets for specific
neuropsychiatric symptoms.Introduction
Neuregulins (NRGs) comprise a large family of widely expressed
epidermal growth factor (EGF)-like proteins that have been impli-
cated in neural development and brain activity homeostasis.
NRG1 was the first member of the family to be discovered,
22 years ago, for very different biological functions, including
activation of ERBB receptors, stimulation of Schwann cell
growth, and induction of acetylcholine receptor expression (Falls,
2003; Mei and Xiong, 2008). Since then, five additional NRG
genes (NRG2,NRG3,NRG4,NRG5, andNRG6) have been iden-
tified (Figure 1). Each NRG gene gives rise to multiple splice iso-
forms (>30 for NRG1 and >15 for NRG3, for example) (Kao et al.,
2010;Mei and Xiong, 2008). Immature NRGs are transmembrane
proteins, which release (upon proteolytic processing) soluble
N-terminal moieties that contain the EGF-like signaling domain
(Figure 2). NRGs and related EGF domain-containing proteins
interact with and activate receptor tyrosine kinases of the
ERBB family, each of which initiates intracellular signaling path-
ways in a specificway, including noncanonical mechanisms (Fig-
ures 1 and 2). Nrg/Erbb signaling has been implicated in neural
development including circuitry generation, axon ensheathment,
neurotransmission, and synaptic plasticity. Several members of
this signaling network are encoded by susceptibility genes of
psychiatric disorders like SZ, bipolar disorder, or depression.
Here we review recent progress in identifying Nrg/Erbb
signaling functions in the developing and adult nervous system,
the involvement of the human NRG and ERBB genes in neuro-
psychiatric diseases, and suggested pathophysiological mecha-
nisms of abnormal NRG/ERBB signaling. For comprehensive
reviews on the molecular diversity of the NRG/ERBB network,
see also Britsch (2007), Buonanno and Fischbach (2001), Corfas
et al. (2004), Esper et al. (2006), Falls (2003), Mei and Xiong
(2008), Nave and Salzer (2006), and Rico and Marı´n (2011).Assembly of Neuronal Circuitry
In the developing cortex, most glutamatergic neurons are born in
ventricular and subventricular zones and populate the cortex via
radial migration. This is in contrast to GABAergic interneurons,
which are generated in ganglionic eminences and migrate
tangentially for their destination (Corbin et al., 2001; Franco
and Mu¨ller, 2013; Ghashghaei et al., 2007; Marı´n and Ruben-
stein, 2003; Me´tin et al., 2006; Nadarajah and Parnavelas,
2002). After migration, both types of neurons differentiate to
generate axons and dendrites that form an increasingly complex
circuitry in the brain. Nrg/Erbb signaling is involved at multiple
stages of cortical circuit development. First, we will focus on
their roles in assembling the GABAergic circuit. We will then
discuss their implications in building the glutamatergic circuit.
Nrg and Erbb kinases, in particular Erbb4, are critical for
the assembly of the GABAergic circuitry including interneuron
migration, axon and dendrite development, and synapse forma-
tion (Figure 3). As early as embryonic day 13 (E13) in the mouse,
Erbb4 is present on progenitors in the median ganglionic
eminence (MGE) where interneurons are born and later in
tangentially migrating Dlx+ neurons (Yau et al., 2003). In adult
brains, Erbb4 transcripts have been localized to regions where
interneurons are enriched (Lai and Lemke, 1991; Woo et al.,
2007). The protein is found in hippocampal neurons that are
GAD positive (Huang et al., 2000) and neurons that express par-
valbumin (PV) and somatostatin (Abe et al., 2011; Fazzari et al.,
2010; Fox and Kornblum, 2005; Neddens and Buonanno,
2011; Vullhorst et al., 2009; Woo et al., 2007; Yau et al., 2003).
Recent studies suggest that Erbb4 is expressed exclusively in in-
terneurons and not at all in excitatory neurons at postnatal or
adult stage (Vullhorst et al., 2009; Fazzari et al., 2010). At the sub-
cellular level, Erbb4 was shown to be in axonal terminals of inter-
neurons by electron microscopy or immunofluorescenceNeuron 83, July 2, 2014 ª2014 Elsevier Inc. 27
Figure 1. NRG-ERBB Canonical Signaling
NRGs are encoded by six individual genes NRG1,
NRG2, NRG3, NRG4, NRG5, and NRG 6 (Carra-
way et al., 1997; Chang et al., 1997; Harari et al.,
1999; Howard et al., 2005; Kanemoto et al., 2001;
Kinugasa et al., 2004; Uchida et al., 1999; Wata-
nabe et al., 1995; Zhang et al., 1997). NRG1 has six
Types (I–VI), each with a distinct N terminus, Ig
domain, and/or cysteine-rich domain. NRG1 Type
I was identified as heregulin, neu differentiation
factor (NDF), and acetyl choline receptor-inducing
activity (ARIA) (Holmes et al., 1992; Peles et al.,
1992). Types II and III were identified as glial
growth factor (GGF) (Lemke and Brockes, 1984)
and sensory and motor neuron-derived factor
(SMDF), respectively (Ho et al., 1995). NRG5 is
also called tomoregulin or transmembrane protein
with EGF-like and two follistatin-like domains 1
(TMEFF1), whereas NRG6 could be referred as
neuroglycan C, chondroitin sulfate proteoglycan 5 (CSPG5), or chicken acidic leucine-rich EGF-like domain containing brain protein (CALEB). NRGs are syn-
thesized as transmembrane proteins and display an extracellular EGF-like domain, which is essential for ERBB receptor binding. ERBB tyrosine kinases have four
members, EGFR/ERBB1, ERBB2, ERBB3, and ERBB4, each of which has a unique group of ligands except ERBB2, whose ligand remains unknown. ERBB3
kinase activity is impaired (indicated by a cross). Ligand binding causes dimerization and activation of ERBBs, and subsequent phosphorylation of the intracellular
domains (ICDs), and creates docking sites for adaptor proteins including Grb2 and Shc for Erk activation and for p85 for PI3K activation, and for Src kinases, Pyk2
and Cdk5, and PLCg. Ligands and ERBBs are color matched, those in light blue bind both to EGFR and ERBB4 and those in red bind both to ERBB3 and ERBB4.
Abbreviations are the following: AREG, amphiregulin; BTC, b-cellulin; CSPG5, chondroitin sulfate proteoglycan 5; CTF, C-terminal fragment; CALEB, chicken
acidic leucine-rich EGF-like domain containing brain protein; ECD, extracellular domain; EGF, epidermal growth factor; EGFR, EGF receptor; EPGN, epigen; EPR,
epiregulin; Grb2, growth factor receptor-bound protein 2; HBEGF, heparin-binding EGF-like growth factor; ICD, intracellular domain; Ig, immunoglobin; LDLR-B,
LDL receptor class B; Shc, SRC-homology domain-containing; Stat5, signal transducer and activator of transcription 5; TGFa, transforming growth factor-a.; and
TMEFF1, transmembrane protein with EGF-like and two follistatin-like domains 1.
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notion was challenged (Neddens and Buonanno, 2011; Neddens
et al., 2009). Erbb4 has also been found on the postsynaptic site
of excitatory and inhibitory synapses in GABAergic interneurons
(Fazzari et al., 2010; Huang et al., 2001; Krivosheya et al., 2008;
Vullhorst et al., 2009; Woo et al., 2007) (Figure 3).
Two models have been proposed to explain how Nrg1 may
participate in interneuron migration during cortical development.
In one, Erbb4-expressing interneurons, in response to attractive,
soluble Nrg1 Type I in the cortex, migrate on a permissive
corridor of Nrg1 through the developing striatum (Flames et al.,
2004). In the other, Nrg1 and Nrg3 act as repellants that funnel
interneurons as they migrate from the MGE to cortical destina-
tions (Li et al., 2012a). Regardless, GABAergic interneurons are
reduced in the cortex of Erbb4 mutant mice, which supports a
role for Erbb4 in tangential migration (Fisahn et al., 2009; Flames
et al., 2004; Li et al., 2012a; Schmucker et al., 2003). It remains
unclear, however, if genesis and/or survival of interneurons are
altered in the mutant. Intriguingly, viral deletion of the floxed
Erbb4 gene at E13.5 has little effect on the number and distribu-
tion of interneurons in cortical layers (Fazzari et al., 2010). This
may be due to a critical time window (prior to E13.5) for Erbb4
regulation of interneuron migration or to a slow turnover of
Erbb4 protein after gene deletion.
In addition to their role in regulating aspects of interneuron
migration, Nrg1/Erbb4 signaling mechanisms have also been
suggested to contribute to axon and dendrite development of
GABAergic neurons, at least in vitro. Treating hippocampal
cultures (from Gad65-GFP transgenic mice) with recombinant
Nrg1 promotes axon elongation and branching of labeled
interneurons (Fazzari et al., 2010). Nrg1 stimulates dendritic
arborization of wild-type (but not Erbb4-deficient) hippocampal
neurons, in a manner that requires the activity of Erbb4 and28 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.downstream PI3 kinase (Krivosheya et al., 2008). A recent report
indicates that interneuronal Erbb4 colocalizes with kalirin-7, a
dendritic Rac-GEF, and phosphorylates kalirin-7 on Y1663 via
Src kinase (Cahill et al., 2012). Mutation of Y1663 in kalirin-7
blocks Nrg1-mediated increase of dendritic length, suggesting
the involvement of kalirin-7 signaling in dendritic development.
These observations also suggest that Nrg1, via Erbb4, promotes
migration and development of processes in interneurons
(Figure 3Ca).
Nrg/Erbb signaling also contributes to synapse formation in
these circuits. It promotes the formation and maturation of
excitatory synapses on GABAergic interneurons, as quantified
by PSD-95 and GluA1-positive puncta and miniature excitatory
postsynaptic potential (mEPSC) frequency (Abe et al., 2011;
Del Pino et al., 2013; Ting et al., 2011) (Figures 3B and 3Ca).
Erbb4 overexpression and inactivation in Gad65+ interneurons
increases and decreases, respectively, the staining intensity of
synaptophysin and vGlut1, both markers of excitatory axon ter-
minals (Krivosheya et al., 2008). In vivo genetic deletion of Erbb4
in interneurons (using Dlx5/6-Cre, PV-Cre, Lhx6-Cre mice) re-
duces mEPSC frequency and the density of vGlut-1+ terminals
in PV+ interneurons of the hippocampus (Del Pino et al., 2013;
Fazzari et al., 2010; Ting et al., 2011). However, in the medial
prefrontal cortex, Erbb4 is required only for maturation, but not
initial formation, of glutamatergic synapses on PV+ fast-spiking
neurons in vivo (Yang et al., 2013b), perhaps reflecting a regional
difference. The effect of Erbb4 on excitatory synapses may be
mediated by stabilizing PSD-95 (Ting et al., 2011), which is
known to promote the maturation of glutamatergic synapses
(El-Husseini et al., 2000) (Figures 3B and 3Ca). In addition,
postsynaptic Erbb4 may regulate presynaptic differentiation by
transsynaptic interaction with transmembrane Nrg1 or another
binding partner (Krivosheya et al., 2008) (Figure 3Ca).
Figure 2. Nrg1 Noncanonical Signaling
Nrg1 is cleaved by extracellular proteases including BACE1 (or disintegrin or ADAM) (Hu et al., 2006; Luo et al., 2011; Savonenko et al., 2008; Velanac et al., 2012;
Willem et al., 2006) and neuropsin to release soluble, mature Nrg1 that contains the EGF-like domain (Tamura et al., 2012). Soluble Nrg1 binds and activates Erbb
kinases to activate the canonical pathways, although soluble Nrg1-induced endocytosis of GABA-A receptor a1 was independent of Erbb4 kinase (Mitchell et al.,
2013) (Box I) (see Figure 1). Pro-Nrg1 and mature Type III may function as receptor of soluble, extracellular domain of Erbb4 to initiate backward signaling
(Hancock et al., 2008; Zhong et al., 2008) (Box II). Transmembrane Nrg1s could directly interact with transmembrane Erbb4 or other proteins to signal in a cell-
adhesion-dependent manner, some of which may be kinase independent (Chen et al., 2008, 2010a; Del Pino et al., 2013; Fazzari et al., 2010; Krivosheya et al.,
2008) (Box III). Cleavage of Nrg1- or Erbb4-C-terminal fragments (CTFs) give rise to respective intracellular domains (ICDs) that are believed to signal into the
nucleus (Bao et al., 2003, 2004; Lee et al., 2002; Ni et al., 2001; Sardi et al., 2006) (Boxes IV and V).
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and maintenance of GABAergic synapses onto pyramidal neu-
rons. Chandelier cells lacking Erbb4 make fewer synapses
onto the axon initial segments of pyramidal neurons of the hippo-
campus in vivo (Del Pino et al., 2013; Fazzari et al., 2010). Addi-
tionally, the density of interneuron axonal boutons of chandelier
cells is increased by overexpressing Nrg1 Type III in pyramidal
neurons (Fazzari et al., 2010). This effect, which was not
observed on PV+ basket cell synapses (Del Pino et al., 2013),
may be mediated by presynaptic Erbb4 interacting with Nrg1
Type III (Fazzari et al., 2010) (Figures 3B and 3Cb).
On the other hand, the role of Nrg1/Erbb4 signaling in syna-
ptogenesis between interneurons is largely unknown. In cultures
of hippocampal GABA+ neurons, Nrg1 had no effect on puncta
number and size of gephyrin, a postsynaptic scaffold protein of
inhibitory synapses (Ting et al., 2011). However, ectopic expres-
sion and shRNA-mediated knockdown of Erbb4 in hippocampal
GABAergic neurons were shown to increase and decrease,
respectively, the intensity, but not density of vGAT-positive
puncta or Syn clusters in Gad65+ neurons (Krivosheya et al.,
2008). This suggests that Erbb4 may be necessary for matura-
tion of GABAergic synapses in hippocampal interneurons, pre-
sumably via interacting with presynaptic, transmembrane Nrg1
(or other ligands) (Krivosheya et al., 2008) (Figures 3B and3Cc). In a recent in vivo study, however, Erbb4 was shown to
be dispensable for the formation and maturation of GABAergic
synapses on PV+ fast-spiking basket cells in medial PFC (Yang
et al., 2013b).
Nrg1/Erbb signaling is thought to regulate many stages of
glutamatergic circuit assembly including radial migration of pyra-
midal neurons, neurite development, and formation of excitatory
synapses. Recent genetic studies have called for revisiting some
established models and provided insight into underlying mecha-
nisms. Soluble Nrg1 Type II, originally identified as ‘‘glial growth
factor,’’ was thought to stimulate radial glia formation and thus
promote radial neuronal migration. In imprint assays in vitro,
Type II promotes cortical neuronal migration on radial glia (Anton
et al., 1997). In coculture with astroglia, cerebellar granule cells
release Nrg1 to induce radial glial morphogenesis and promote
the migration of granule cells along radial glia (Rio et al., 1997).
In vivo, deletion of Nrg1 in multipotential progenitors of embry-
onic forebrains (E12.5, by Emx-Cre), in newborn projection neu-
rons of the cortex (E12.5, by Nex-Cre), or in the developing CNS
(E11.5, by nestin-Cre) has no effect on cortical lamination and
hippocampal formation (Brinkmann et al., 2008). Moreover, the
development of radial glial and astrocytes is normal in mutant
mice in which Erbb2 and Erbb4 were both ablated in neural pre-
cursors at E8.5, E10.5, and E13.5 (by Nestin8-Cre, Emx1-Cre,Neuron 83, July 2, 2014 ª2014 Elsevier Inc. 29
Figure 3. Nrg1 and Erbb4 in Neural Circuitry Assembly
(A) Regulation of migration and differentiation of GABAergic interneurons, including development of neuronal processes and synapse formation.
(Ba–Bd) Schematic diagram of inhibitory and excitatory circuitries.
(Ca–Cd) Cellular mechanisms of Nrg1 and Erbb4 in forming inhibitory and excitatory synapses onto inhibitory and excitatory neurons. tmNrg1, transmembrane
Nrg1 including Type III Nrg1 and proNrg1; sNrg, soluble Nrg1. See text for details.
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or Erbb4 single mutants, these mice exhibit no abnormality in
laminal structure of the cerebral cortex, hippocampus, and cer-
ebellum or loss of neuronal density in any cortical layer (Barros
et al., 2009; Pitcher et al., 2008). Thus, loss-of-function studies
in vivo suggest that Nrg1/Erbb signaling is dispensable for radial
glia differentiation and radial migration of cortical neurons.
Nrg1 has also been shown to stimulate neurite outgrowth
of excitatory neurons including hippocampal neurons and ce-
rebellar granule cells (Gerecke et al., 2004; Murphy and Bielby-
Clarke, 2008; Rio et al., 1997). This effect only occurs in Erbb4+
neurons (Cahill et al., 2012; Krivosheya et al., 2008), which
are mostly GABAergic interneurons (see above) (Figure 3Ca).
This may explain why viable (‘‘heart-rescued’’) Erbb4 mut-
ant mice or conditional Erbb2/Erbb4 double mutants (using
hGFAP-Cre to target neural precursors) showed normal dendritic
morphology of cortical and hippocampal neurons (Barros et al.,
2009). Perturbed basal dendrites and axon elaboration in cortical
neurons inNrg1 Type IIImutant mice are thought to be mediated
by the intracellular domain (ICD) in so-called backward signaling
(Chen et al., 2008, 2010a) (Figure 3Cd). Although the mecha-30 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.nisms for this effect are unknown, the ICD of Nrg1 can regulate
gene expression (Bao et al., 2003, 2004).
Regarding excitatory synapse formation on pyramidal neu-
rons, conditional deletion of Erbb2 and Erbb4 in single and dou-
ble mutant mice (generated by hGFAP-Cre) reduced dendritic
spine density in hippocampal and cortical neurons (Barros
et al., 2009). Moreover, lentiviral infection of hippocampal slices
to knockdown Erbb4 impairs spine formation (Li et al., 2007).
These results are indicative of a necessary role of Nrg1/Erbb
signaling. As discussed above, Erbb4 expression in the brain is
restricted to interneurons in postnatal or adult animals (Fazzari
et al., 2010; Vullhorst et al., 2009). Besides, deletion of Erbb4
in pyramidal neurons of floxed Erbb4 mice (by retroviral Cre or
by CaMKII-Cre) did not alter the density of dendritic spines or
mEPSC (Fazzari et al., 2010; Yin et al., 2013b) and Erbb4 knock-
down in cultured hippocampal neurons had no effect on Nrg1
induction of spines (Cahill et al., 2013). Spine reduction in mice
where Erbb4 was knocked out by hGFAP-Cre or in hippocampal
slices by lentivirus may be due to a homeostatic mechanism to
compensate hyperactivity of pyramidal neurons (because of hy-
pofunction of GABAergic circuitry) (see below). In support of this
Neuron
Reviewnotion, spines are reduced in mice that lack Erbb4 in PV+ inter-
neurons (Del Pino et al., 2013; Yin et al., 2013b). Alternatively, the
spine deficit may be caused by loss of Erbb4 that is transiently
expressed in a subset of excitatory neurons during development.
Nrg1 has been implicated in synthesis of neurotransmitter
receptors. First identified as an acetylcholine receptor (Achr)-
inducing activity (ARIA), it was thought to control synapse-spe-
cific gene expression and formation of the peripheral synapse
(Falls et al., 1993; Sandrock et al., 1997). However, in mice lack-
ing Nrg1 in motoneurons, muscle fibers, or both cell types, Achr
expression and clusters are normal (Jaworski and Burden, 2006).
Moreover,mice that lackErbb2 andErbb4 inmuscle fibers in vivo
are able to form mature endplates (Escher et al., 2005; Schmidt
et al., 2011). Thus, in knockout mouse models, Nrg1/Erbb
signaling is dispensable for neuromuscular junction develop-
ment and its biological function remains to be defined. Long-
term treatment of brain slices or neurons with Nrg1 has also
been shown to alter the expression or activity of NMDA recep-
tors, metabotropic glutamate receptors, GABA-A receptors,
and neuronal Achr in cultured neurons or slices (Liu et al.,
2001; Okada and Corfas, 2004; Ozaki et al., 1997; Rieff et al.,
1999; Schapansky et al., 2009). However, double knockout of
Erbb2 and Erbb4 by hGFAP-Cre or by BACa6-Cre had no effect
on expression of NMDA receptors or GABA-A receptors in vivo
(Barros et al., 2009; Gajendran et al., 2009).
Myelination of Axonal Processes
Nrg1/Erbb signaling, which is key to neuronal circuit formation, is
also important for the communication of projection neurons with
axon-associated glial cells for the purpose of myelination. Myelin
serves the rapid axonal impulse propagation, which is essential
for long-range connectivity. To achieve myelination, oligoden-
drocytes (in the CNS) and Schwann cells (in the PNS) engage
in complex interactions with axonal segments that become
spirally enwrapped (Snaidero et al., 2014), resulting in the forma-
tion of electrically insulated ‘‘internodes,’’ separated only by
widely spaced nodes of Ranvier (Emery, 2010; Nave, 2010). In
higher vertebrates, myelin sheaths provide the physical basis
for ‘‘saltatory’’ impulse propagation, which is essential for normal
motor and sensory functions. In addition, myelinating glia help
maintain the functional integrity and survival of axons (Griffiths
et al., 1998), possibly by directly supporting the axonal energy
balance (Fu¨nfschilling et al., 2012; Lee et al., 2012). Fine-tuning
of myelin sheath thickness and conduction velocity is critical to
maintain the temporal precision of long-range connectivity in
the brain in the millisecond range. This may explain why human
psychiatric diseases have been repeatedly associated with
myelin and white matter abnormalities (Fields, 2008; Nave and
Ehrenreich, 2014). An important research goal is to better under-
stand the mechanisms by which glial cells select axons for mye-
lination and are instructed to wrap the optimal number of myelin
membrane layers such that the correct g ratio (axonal diameter/
myelinated fiber diameter) is reached and maintained.
At least in the PNS, axonal Nrg1 is a key signaling molecule
that regulates the behavior of myelinating Schwann cells. When
Schwann cells are maintained in culture, they can be stimulated
by purified axonal membranes to proliferate (McCarthy and Par-
tlow, 1976;Salzer andBunge, 1980;WoodandBunge, 1975). Theresponsible factor, glia growth factor orNrg1 Type II, was purified
and found to cause fibroblasts, Schwann cells, and astrocytes to
divide (Lemke and Brockes, 1984) (Figure 1). Also recombinant
soluble Nrg1 Type I maintains the survival of cultured Schwann
cells (Dong et al., 1995) and can be used in the laboratory for
Schwann cell expansion in vitro. In vivo, however, the critical
Schwanncell growth factor isNrg1Type III, a protein that remains
associated with axonal membranes bymeans of a secondmem-
brane anchor. By in situ hybridization, Type III is indeed the most
prominent Nrg1 isoform in motoneurons of the spinal cord and
sensory neurons of dorsal root ganglia.
As Nrg1 null mutant mice die with a developmental heart
failure at E11 (Meyer and Birchmeier, 1995), i.e., without informa-
tive pathology of the nervous system, the first in vivo evidence
for a critical function of Nrg1/Erbb signaling in the PNS came
from mutant mice lacking Erbb3 (Riethmacher et al., 1997).
Some mutant embryos develop to term but die shortly after,
with breathing defects that constitute a lethal ‘‘neuropathy’’
phenotype. Interestingly, there was not only a complete lack of
Schwann cells frommutant nerves, but also a loss of themajority
of sensory dorsal root ganglia (DRG) neurons and spinal motor
neurons, which are Erbb3 negative. This suggested a potential
neurotropic function of Schwann cells for the survival of associ-
ated neurons.
Schwann cells express both Erbb2 and Erbb3 but not Erbb4.
While Erbb2 has a strong kinase domain, it lacks receptor func-
tions and requires heterodimerization with Erbb3 for Nrg1 signal
transduction. Erbb3, in turn, is a functional receptor but weak
kinase (Figure 1). In a first gene-targeting experiment, the floxed
Erbb2 gene was selectively eliminated in Schwann cells that had
matured enough to express a Krox20-Cre transgene (Garratt
et al., 2000). At this stage, neurons and Schwann cells are no
longer mutually dependent for survival (Meier et al., 1999).
Thus, the resulting neuropathy phenotype was no longer lethal
but severe enough to confirm the critical role of Erbb2 signaling
for Schwann cell expansion and therefore myelination. Interest-
ingly, when the floxed Erbb3 gene was inactivated in Cnp-Cre
mice, peripheral dysmyelination was much more severe (Brink-
mann et al., 2008), suggesting that a lack of Erbb2 fromSchwann
cells can be partially compensated for by the presence of Erbb3,
but not vice versa. This is in agreement with a recent report of
low but significant kinase activity of Erbb3 that is sufficient for
autophosphorylation (Shi et al., 2010).
Nrg1 Type III is targeted into long axonal projections where it
has multiple functions. This isoform has been implicated in
axonal pathfinding of TrkA+ sensory neurons in response to
Sema3A, a guidance cue in the developing spinal cord and in
the periphery (Hancock et al., 2011) and in regulating functional
TRPV1 along sensory neuron axons for heat sensing (Canetta
et al., 2011). Its most important function is the control of
Schwann cell development and peripheral myelination. Mutant
embryos that lack selectively this membrane-associated isoform
develop to term (Wolpowitz et al., 2000), but perinatal death
in these mice is associated with a striking lack of Schwann
cells and a severe reduction of DRG and motor neurons, similar
to observations in Erbb3 mutants. This implicates the Nrg1
Type III isoform as essential for normal Schwann cell develop-
ment. However, is there also a direct role in myelination?Neuron 83, July 2, 2014 ª2014 Elsevier Inc. 31
Figure 4. Nrg1 Type III in Schwann Cell
Myelination
(A) Schematic depiction of Schwann cells and their
precursors (in blue) stimulated by axons (in cross-
section, brown) through all stages of the Schwann
cell lineage, i.e., from the proliferating precursors
(left) tomyelinating Schwann cells (right). Glial Erbb
receptors (green) integrate Nrg1 Type III (red)
signals from the axon surface, generating intra-
cellular second messenger signals as surrogates
of axon size. Thus, threshold levels of axonal NRG1
initiate myelination once the axon caliber mea-
sures about 1 mm.
(B) Transgenic overexpression of Nrg1 Type III in-
creases the density of this ligand on the axon
surface, causing significant hypermyelination,
without increase of axon caliber.
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ReviewThe first ‘‘gain-of-function’’ experiments, in which in vitro mye-
lination by DRG/Schwann cell cocultures was assessed in the
presence of soluble Nrg1, reported a striking ‘‘demyelination’’
phenotype (Zanazzi et al., 2001). In hindsight, this may have
been caused by an unphysiological presentation of Nrg1 as a
soluble factor and/or the overstimulation of one of several sec-
ond messenger pathways in Schwann cells (Syed et al., 2010).
When Nrg1 was neuronally overexpressed in transgenic mice
as an axonal surface signal and at later developmental stages,
it emerged as a myelination-promoting signal (Michailov et al.,
2004). Moreover, by comparing transgenic mice expressing
either Type I or Type III cDNA transgenes (both under control
of the Thy1 promoter in DRG and motoneurons) only Nrg1
Type III emerged as the regulator of myelination. Its overexpres-
sion caused Schwann cells to ‘‘hypermyelinate’’ axons in periph-
eral nerves (Figure 4), as demonstrated by g ratio quantification.
In turn, loss of gene dosage (in either heterozygous Nrg1 null or
heterozygous Nrg1 Type III-null mice) caused significant ‘‘hypo-
myelination.’’ This suggests that in axons of the PNS, the steady-
state level of Nrg1 is mainly regulated at the transcriptional level
and that Nrg1 Type III expression is rate limiting for peripheral
myelination. In contrast, heterozygosity of Erbb2 reduced the
expression level of this receptor but had no effect onmyelination,
in line with observations in the neurotrophin field that reduced
levels of ligands (not receptors) often limit transcellular signaling.
Together, these observations identified an important develop-
mental function of Nrg1 Type III. According to this model, the
total amount of Nrg1 Type III that is presented on the axonal
surface provides the information about axon size to associated
Schwann cells (Michailov et al., 2004). The strength of this signal
determines the amount of myelin membrane synthesis that
matches axon caliber and yields the ‘‘optimal’’ g ratio for nerve
conduction. A major unresolved question is how the rate of
neuronal Nrg1 expression is regulated in the first place, i.e., as
a function of axon caliber and length, and how axonal Nrg132 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.Type III affects expression of the glial
Erbb gene itself (Schulz et al., 2014) and
thus Schwann cell responsiveness.
In PNS development, large axons are
sorted and individually myelinated by
associated Schwann cells, whereas C
fiber axons with a diameter <1 mm are en-gulfed in groups (‘‘Remak bundles’’) by so-called ‘‘nonmyelinat-
ing’’ Schwann cells. This sorting is determined by axon size, as
demonstrated in a classic experiment (Voyvodic, 1989), in which
sympathetic C fiber axons of the submandibular salivary gland
became artificially enlarged after hemisection of the nerve (and
increased neurotropic supply to the surviving axons). This radial
growth of sympathetic axons triggered the associated Schwann
cells to sort and myelinate them. Expression level of axonal
Nrg1 may provide information about axon size. In cocultures
of nonmyelinated sympathetic ganglion neurons from Nrg1
Type III null mutantmice andSchwann cells, the viral overexpres-
sionofNrg1Type III in neuronscausesSchwanncells to ensheath
individual axons (Taveggia et al., 2005). Conversely, in Nrg1
Type III isoform-specific heterozygousmice, a greater proportion
of small caliber axons remained unsorted, and in Nrg1 Type III
null mutants even large-caliber axons remain completely unen-
sheathed (Taveggia et al., 2005). Although continued Nrg1/Erbb
signaling is not required once myelination has been completed
(Atanasoski et al., 2006; Fricker et al., 2009), myelin repair in
the peripheral nerves of adult mice recapitulates some of the
developmental steps and depends on Nrg1/Erbb signaling but
is considerably more complex (see below).
Nrg1/Erbb-Dependent Second Messenger Pathways
in Schwann Cells
In PNS development, neuronal Nrg1 Type III molecules are pre-
sented on the axon surface, where they stimulate the associated
Schwann cell to initiate sorting and myelination. It is therefore
puzzling that 20 or more C fiber axons (<1 mm in diameter) can
be associated with a single Schwann cell (in a ‘‘Remak bundle’’)
without reaching in sum the ‘‘threshold level’’ of stimulation that
is obviously reached by a single axon >1 mm in diameter. This
paradox might be explained by Erbb2/Erbb3 downstream
mechanisms that initiate membrane outgrowth by altering actin
and membrane dynamics and that act locally at each axon-glia
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PI3K at the cell membrane (Heller et al., 2014) is likely regulated
by the polarity of myelinating Schwann cells toward a single
axon, which Remak cells may not show as such toward the
many axons they engulf. In other systems, PI3K-dependent
elevation of phosphoinositide-3,4,5-triphosphate (PIP3) recruits
proteins that establish cell polarity, such as Par3, which is
essential for myelination (Chan et al., 2006). Interestingly, Par3
localizes at the axonal interface of Schwann also as a result
of BDNF signaling, i.e., possibly independent of Nrg1/Erbb
signaling (Tep et al., 2012).
The response of Schwann cells to axonal Nrg1 is complex. The
Erbb2 kinase has been shown to associate with Erbin, a PDZ-
domain scaffold protein with multiple leucine-rich repeats
(Borg et al., 2000; Huang et al., 2001), and this interaction may
regulate Nrg1 signaling by regulating Erbb2 stability or MAP
kinase pathway (Huang et al., 2003; Tao et al., 2009). Erbin has
also has been implicated in myelin formation and remyelination
after injury (Liang et al., 2012; Tao et al., 2009). Another Erbb-
associated scaffolding protein required for myelination is Grb2-
associated binder-1 (Gab1) (Shin et al., 2014).
Erbb receptor activation triggers multiple second messengers
in Schwann cells (for details see also Colognato and Tzvetanova,
2011; Taveggia et al., 2010). Activation of the PI3K/Akt/mTOR
pathway (Maurel and Salzer, 2000; Taveggia et al., 2005), the
Shp2/Erk/MAPK pathway (Grossmann et al., 2009; Newbern
et al., 2011), and the PLC/Calcineurin/NFAT pathway (Kao
et al., 2009) are all critical for myelination (Figure 1). These path-
ways affect Schwann cells and their gene expression program
rather globally. In contrast, Nrg1/Erbb-dependent and integrin-
mediated stimulation of focal adhesion kinase (FAK) and the
small GTPases Cdc42 and Rac1 provide additional local signals
at the axon-glial interface. These enhance actin dynamics under-
neath the Schwann cell membrane and enable the very first
steps of myelination, i.e., radial sorting of axons (Grove et al.,
2007) and initial membrane outgrowth (Benninger et al., 2007;
Nodari et al., 2007).
Indeed, experimental elevation of the lipid phosphatidylinosi-
tol-(3,4,5)-trisphosphate (PIP3) in mutant Schwann cells that
lack the lipid phosphatase PTEN is associated with hypermyeli-
nation of small axons.Moreover, there is abnormal wrapping of C
fiber axons but this ‘‘myelin’’ is not compacted (Goebbels et al.,
2010). C fiber wrapping is not seen when a constitutive active
form of Akt is overexpressed in Schwann cells (Flores et al.,
2008). Thus, enhanced PI3K signaling is clearly only part of the
complex Schwann cell response to Nrg1 Type III. By itself,
elevated PIP3may promote membrane outgrowth and wrapping
but, in the absence of Erk/MAPK stimulation, not the entire pro-
gram of myelination. In the same PTEN-deficient conditional
mouse mutants, larger axons develop abnormal myelin hyper-
growth (‘‘tomacula’’) with all the features of human tomacular
neuropathy (Goebbels et al., 2012). Taken together, careful regu-
lation of the (Nrg1 Type III-dependent) PI3K/Akt/mTOR pathway
is also important in adult mice in that PTEN puts a local ‘‘brake’’
on abnormal myelin synthesis (Cotter et al., 2010). Interestingly,
activation of the Erk/MAPK pathway, which plays a major role in
Nrg1-induced peripheral myelination (Newbern and Birchmeier,
2010), can cause hypermyelination under experimental condi-tions, without corresponding changes of myelin gene transcrip-
tion. This suggests a major role of posttranscriptional regulation
of myelin growth (Sheean et al., 2014).
Processing of Nrg1 Activates a Myelination Signal
Biologically active Nrg1 is generated by proteolytic processing
from a larger membrane-bound precursor protein, which promp-
ted the analysis of neuronal metalloproteases as candidate
‘‘sheddases’’ (Figure 2). These experiments identified b-secre-
tase BACE1, already well known for its ability to process the
amyloid precursor protein, as a critical enzyme for the activation
of Nrg1. Indirect evidence included the abundance of ‘‘full-
length’’ Nrg1 in the brains of Bace1 null mutant mice, which
have a hypomyelinated phenotype specifically in the PNS
(Hu et al., 2006, 2008; Luo et al., 2011; Treiber et al., 2012;Willem
et al., 2006). Myelin sheath thickness is an easily quantifiable
readout for Nrg1 activity and its modulation by prior protein pro-
cessing. Bace1 is likely not the only relevant protease, because
in Bace1 null mutant mice there is a residual presence of pro-
cessed Nrg1 isoforms (Velanac et al., 2012). As for Type III, it is
still unclear whether the proteolytic processing is essential for
biological activity, or whether pro-Nrg1 can stimulate Schwann
cells to some extent. Additional complexity of Nrg1 processing
emerged with the finding that the metalloprotease TACE1
(‘‘tumor necrosis factor-alpha converting enzyme’’/ADAM17)
also digests membrane-bound Nrg1 (Montero et al., 2000) but
closer to the EGF-like domain and presumably antagonizing
the role of BACE1 as a myelination-promoting factor (La Marca
et al., 2011). At least in the PNS, the b1 splice variant of Nrg1
(Falls, 2003) is by far the most abundant one. Other isoforms
of the juxtamembrane region have not been analyzed in detail,
and it is possible that these sequence differences affect
proteolytic processing. Finally, the zinc protease Nardilysin
(‘‘N-Arginine dibasic convertase’’/NRDc) activates other metal-
loproteases, i.e., TACE1 (Nishi et al., 2006) and BACE1 (Ohno
et al., 2009), and thus promotes Nrg1 processing and myelina-
tion, as evidenced by the hypomyelinated phenotype of NRDc
mutant mice. The discovery that ‘‘activated’’ Nrg1 Type III can
be further processed leading to the release of the EGF domain
(Fleck et al., 2013) suggests that the paracrine signal may also
diffuse in the periaxonal space before binding to Erbb receptors
on the adaxonal Schwann cell surface.
Given that the shedding of Nrg1 from axons can also be regu-
lated by glial-derived neurotrophins, developmentally regulated
Nrg1 processing is clearly complex. We assume that similar
neuronal proteases activate synaptic Nrg1/Erbb signaling (see
below), but this has not been formally shown. Equally important,
the relevant subcellular compartments in which Nrg1 processing
takes place remain to be defined and this may be different for
neuron-to-neuron and neuron-to-glia signaling.
Schwann Cell-Derived Nrg1 Type I Promotes
Myelin Repair
When maintained in culture, Schwann cells express Nrg1 Type I
(but not Type II or Type III), but the function of the Type I isoform
has remained obscure. Autocrine stimulation by Nrg1 Type I can
be observed in lung cancer cells that also express Erbb2/Erbb3
receptors (Gollamudi et al., 2004) and similarly in neoplasticNeuron 83, July 2, 2014 ª2014 Elsevier Inc. 33
Figure 5. Nrg1 in Remyelination of the PNS after Nerve Injury
In intact nerves, axonal Nrg1 Type III controls myelination and inhibits Nrg1
Type I expression by Schwann cells. After Wallerian degeneration, Schwann
cells are detached and the axonal Nrg1 Type III signal is lost. At this stage,
expression of Nrg1 Type I by Schwann cells is ‘‘derepressed’’ and promotes
Schwann cell differentiation and remyelination in a transient autocrine/para-
crine signaling loop (from Stassart et al., 2013).
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Type III overexpression can induce Schwann cell transformation
(Danovi et al., 2010). Could an ‘‘autocrine loop’’ of Nrg1/Erbb
signaling also support Schwann cell survival during development
or following nerve injury? When injured axons undergo Wallerian
degeneration and quickly disintegrate, the associated Schwann
cells follow with a rapid dedifferentiation program (Arthur-Farraj
et al., 2012). At this stage, they lack normal axonal contact and
Nrg1 Type III stimulation and begin to transiently upregulate
Nrg1 Type I expression. Exposure to axonal Nrg1 Type III sup-
presses this expression of Nrg1 by Schwann cells, depending
on glial Erbb receptors and MAPK signaling (Stassart et al.,
2013). Specific deletion of Nrg1 from Schwann cells has no
obvious effect on normal development and myelin growth. How-
ever, the remyelination of crushed nerves becomes inefficient
in these conditional mutants (Stassart et al., 2013). Schwann
cell survival is not affected, suggesting that Nrg1 autoregulation
promotes rapid remyelination in the transient absence of this
axonal growth factor (Figure 5).
Schwann cell-derived Nrg1 may also contribute to axonal
regeneration itself (Joung et al., 2010), but whether this is a direct
or indirect effect awaits further analysis. A recent report that re-
myelination (after crush injury of the sciatic nerve) is possible in
adult mice that were made to completely lack Nrg1 from virtually
all cells by b-actin controlled Cre expression and tamoxifen-
induced gene targeting is surprising (Fricker et al., 2013). The
responsible growth factor that might compensate for axonal
Nrg1 remains to be defined. However, precedent for Nrg1-inde-
pendent myelination comes from the CNS.
Distinct Roles in PNS and CNS Myelination
Myelinated neurons in both the PNS andCNS expressNrg1 Type
III. With respect to Nrg1 receptors, Schwann cells and oligoden-
drocytes differ by expressing Erbb2/Erbb3 and Erbb3/Erbb4,34 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.respectively (Vartanian et al., 1997). Despite these similar
expression patterns and even though axons that enter and exit
the spinal cord are clearly myelinated in both PNS and CNS,
unexpectedly, the axonal control of myelination is remarkably
dissimilar in the PNS and CNS. Earlier studies with spinal cord
explant cultures from midgestation (E9.5) Nrg1 null mutant
mice had shown that the failure of oligodendrocyte differentia-
tion in vitro could be rescued by adding recombinant Nrg1 to
the culture medium (Vartanian et al., 1999). Surprisingly, experi-
mental perturbations of Nrg1 signaling in vivo revealed only mi-
nor differences. The conditional inactivation of Nrg1 expression
in mice, using various neuron-specific Cre driver lines, was
compatible with normal CNS myelination (Brinkmann et al.,
2008). Specifically, deletion of Nrg1 in pyramidal neurons of
the cortex (by CaMKII-Cre), in projection neurons of the cortex
(by NEX-Cre), in multipotential progenitors of the embryonic
forebrain (by Emx-Cre), or in the entire CNS (by nestin-Cre)
had no quantifiable effect on the myelination of axons in the
corpus callosum and within the neocortex, or on the branching
and morphology of oligodendrocytes (Brinkmann et al., 2008).
Likewise, Erbb3 and Erbb4 receptors were not required for the
timely differentiation of oligodendrocytes and CNS myelination
(Brinkmann et al., 2008; Schmucker et al., 2003; Tidcombe
et al., 2003), but these double mutant mice could only be fol-
lowed for the first postnatal weeks.
It is currently unclear why the complete lack of Nrg1 expres-
sion in conditional mutants shows less effect on CNS myelina-
tion than mere reduction of Erbb signaling does. The 50% gene
dosage in Nrg1 Type III-specific heterozygous mice (Wolpowitz
et al., 2000) reportedly causes mild hypomyelination of the CNS
(Taveggia et al., 2008) and mice that overexpress a truncated
(dominant-negative) version of the Erbb4 receptor in oligoden-
drocytes show signs of cortical hypomyelination (Roy et al.,
2007). Recently, the same group associated reduced Nrg1-
Erbb signaling within a ‘‘critical period’’ of myelination in the
prefrontal cortex (PFC). Mice separated from their mothers
during early postnatal life (‘‘social isolation stress’’) showed
reduced Nrg1 expression and this was reminiscent of PFC
hypomyelination in conditional mouse mutants lacking Erbb3
from mature oligodendrocytes after tamoxifen induction (Maki-
nodan et al., 2012). Social isolation may reduce the spiking
activity of PFC neurons, thereby perturbing Nrg1-Erbb signaling
and myelination. The alternative possibility must be considered
that isolation-associated stress is coresponsible for perturbing
oligodendrocyte differentiation (Banasr et al., 2007; Cze´h
et al., 2007; reviewed in Edgar and Sibille, 2012). Elevated
cortisol levels have been found to inhibit myelination in the
postnatal brain (Alonso, 2000; Chari et al., 2006). While social
isolation has been independently linked to altered oligodendro-
cyte differentiation (Liu et al., 2012), the mechanism by which
electrical activity would regulate Nrg1 expression awaits to be
determined. In fact, an alternate model has been suggested
based on cell culture data in that Nrg1 triggers the responsive-
ness of oligodendrocyte precursor cells (OPCs) to electrical
activity and glutamatergic signaling by axons, both of which
promote myelination. In cocultures of DRG neurons with OPC,
soluble Nrg1-mediated myelination is dependent on neuronal
activity and is associated with N-methyl-D-aspartate receptor
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aard et al., 2013).
The biological function of neuronal/axonal Nrg1 in the CNS
and for Erbb3 and Erbb4 receptors expressed by oligodendro-
cytes has remained difficult to define by conventional loss-of-
function experiments. In contrast, transgenic overexpression of
Nrg1 Type III (and unexpectedly also Type I) in CNS neurons
under control of the Thy1.2 promoter caused significant hyper-
myelination and some precocious myelination, when quantified
in the optic nerve of early postnatal mice (Brinkmann et al.,
2008). Thus, oligodendrocytes respond to Nrg1 stimulation
in vivo. However, in these experiments, Nrg1 overexpression
levels were very high (5-fold at the RNA and >10-fold at the
protein level), drawing into question the specificity of this obser-
vation. Stimulation of other receptor systems in oligodendro-
cytes that likewise activate PI3K and MAPK pathway exerts
similar effects (Lundgaard et al., 2013). CNS hypermyelination
has been observed many years earlier in transgenic mice that
overexpress IGF1 under control of a ubiquitously active pro-
moter (Carson et al., 1993).
Regulation of Neurotransmission andSynaptic Plasticity
Once postnatal brain development has been completed, Nrg1/
Erbb expression continues in the adult nervous system, most
likely with functions in neurotransmission and neuroplasticity.
In adult brain, Nrg1 and Erbb kinases remain widely expressed
(Mei and Xiong, 2008), and postsynaptic Erbb4 in particular is
enriched at excitatory synapses where it interacts with PSD-95
(Garcia et al., 2000; Huang et al., 2000). Indeed, the treatment
of adult hippocampal slices with soluble Nrg1 (the EGF-like
signaling domain synthesized as a polypeptide) rapidly sup-
presses, in a concentration-dependent manner, the induction
of long-term potentiation (LTP) at Schaffer collateral-CA1 synap-
ses (Huang et al., 2000; Ma et al., 2003). The effect is abolished
by genetic deletion of Erbb4 (Chen et al., 2010b; Pitcher et al.,
2008). Moreover, neutralization of endogenous Nrg1 and muta-
tion of Erbb4 both enhance hippocampal LTP, indicating that
synaptic plasticity is regulated by Nrg1 in vivo (Chen et al.,
2010b; Pitcher et al., 2008; Agarwal et al., 2014).
Glutamate has two major inotropic receptors a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)
and NMDAR. There is a general consensus that Nrg1 does
not change basal synaptic transmission, such as AMPAR- or
NMDAR-induced currents in hippocampal CA1 neurons (Bjarna-
dottir et al., 2007; Chen et al., 2010b; Huang et al., 2001; Iyengar
and Mott, 2008) or in cultured cerebellar granule neurons
(Fenster et al., 2012). Nevertheless, Nrg1 was shown to reduce
AMPAR EPSCs at potentiated synapses, presumably by
increasing AMPAR endocytosis in hippocampal neurons. This
effect was thought to be a responsible mechanism of LTP
reversal by Nrg1 detected 20 min after theta-burst stimulation
(TBS) (Kwon et al., 2005). However, established LTP cannot be
reversed by Nrg1 when applied 30 min after TBS (Pitcher et al.,
2011), which may suggest time dependence of the effect. Nrg1
could also attenuate NMDA receptor currents in PFC neurons
in vitro (Gu et al., 2005). Whether and how these observations
relate to a physiological mechanism by which Nrg1 regulates
synaptic plasticity requires further investigation (see below).Erbb4 is expressed in dopaminergic neurons of the midbrain
(Abe et al., 2009; Neddens and Buonanno, 2011; Steiner et al.,
1999; Zheng et al., 2009). Injection of Nrg1 just dorsal to the
substantia nigra increases dopamine levels in the midbrain
(Yurek et al., 2004). Delivery of Nrg1 into the dorsal CA1 region
increased local dopamine levels within 2 min (Kwon et al.,
2008). Thus, Nrg1 can acutely promote dopaminergic transmis-
sion. This effect was blocked by pharmacological inhibitors of
Erbb4 kinase. How Nrg1 promotes dopamine release remains
unclear because Erbb4 was undetectable on dopaminergic
fibers in the hippocampus or on Gad67+ or TH+ neurons in the
VTA (Kwon et al., 2008). Nrg1 may elevate dopamine release
via a disinhibitory circuit consisting of Erbb4-positive interneu-
rons (Figure 6).
In adult brain, ErbB4 receptors are localized at excitatory syn-
apses on interneurons (Fazzari et al., 2010; Ting et al., 2011).
They are also present in terminals of PV+ basket and chandelier
interneurons (Fazzari et al., 2010; Woo et al., 2007), although
some reports have disputed this view (Neddens and Buonanno,
2011; Vullhorst et al., 2009). One function of Erbb4 is to promote
GABA release, which can be increased by soluble Nrg1 (Chen
et al., 2010b; Woo et al., 2007). This effect cannot be blocked
by inhibition of various neurotransmitter receptors, suggesting
that Nrg1 acts directly on interneurons (Woo et al., 2007). Impor-
tantly, treatment with a neutralizing peptide (or deletion of the
Erbb4 gene) reduces GABAergic transmission, increases the
firing of pyramidal neurons, and enhances LTP in brain slices
(Chen et al., 2010b; Pitcher et al., 2008; Wen et al., 2010; Woo
et al., 2007). These observations suggest that GABAergic activity
may be under control of endogenous Nrg1. By regulating
GABAergic neurotransmission, which is known to be critical for
controlling and synchronizing the activity of pyramidal neurons,
Nrg1 may be involved in a wide spectrum of brain functions,
from autonomic control of blood pressure (Matsukawa et al.,
2013) to cognition (see below). In agreement, gamma oscillation
in slices was reduced in Erbb4 null mutant slices (Fisahn et al.,
2009). Additionally, neuronal activity associated with limbic
seizure increases Nrg1-Erbb4 signaling (Tan et al., 2012). Loss
of Erbb4 from PV+ interneurons promotes kindling progression
and leads to an increase of spontaneous seizures (Li et al.,
2012b; Tan et al., 2012).
How Nrg1 stimulates GABA release from interneurons war-
rants further investigation. One hypothesis posits that the
activation of presynaptic Erbb4 at axon terminals increases
GABA release, because Nrg1 treatment of purified synapto-
somes increases GABA secretion (Woo et al., 2007). Alterna-
tively, Nrg1 was shown to elevate the excitability of fast spiking
PV+ interneurons in mouse cortical layers 2–3, presumably
by inhibiting Kv1.1 in an Erbb4-dependent manner (Li et al.,
2012b). However, such effect was not observed in dissociated
Erbb4-expressing neurons of the hippocampus (Janssen et al.,
2012) or granule cells that respond to Nrg1 (Yao et al., 2013).
Instead, Nrg1 was shown to decrease voltage-gated sodium
channel activity in hippocampal interneurons and thus to
reduce their excitability (Janssen et al., 2012). A recent study
reported that Erbb4 promotes endocytosis of GABAARa1 in
cultured interneurons, in a manner independent of its kinase
activity (Mitchell et al., 2013).Neuron 83, July 2, 2014 ª2014 Elsevier Inc. 35
Figure 6. Nrg1 in Neurotransmission and Synaptic Plasticity
(A and B) Schematic diagrams of circuitry in the CA1 region of the hippocampus.
(Ca) Nrg1 activates Erbb4 in interneurons and promotes GABA release by altering excitability and/or vesicle release to suppress LTP.
(Cb) Nrg1 inhibits Src activation in pyramidal neurons to suppress LTP.
(Cc) Nrg1 stimulates dopamine release in the hippocampus and suppresses LTP in a manner that requires D4R.
(Cd) Transmembrane Nrg1 (tmNrg1) such as Type III initiates backward signaling to promote presynaptic a7-AChR expression, which is required for converting
short-term potentiation (STP) to LTP at cortico-BLA synapses. See text for details.
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hippocampus when Erbb4 is ablated in PV+ cells (Chen et al.,
2010b; Shamir et al., 2012). In comparison, deletion of the
same Erbb4 gene in pyramidal neurons has little effect on LTP
induction or suppression of LTP by Nrg1 (Chen et al., 2010b).
Clearly, Erbb4 in interneurons plays a key role in regulating
LTP, but how? A few models have emerged from recent studies
(Figure 6). In the first model, Nrg1 via activating Erbb4 in inter-
neurons promotes GABAergic transmission and thus inhibits
the firing of pyramidal neurons (Wen et al., 2010) and suppresses
LTP (Chen et al., 2010b) (Figure 6Ca). This model explains Nrg1
suppression of LTP in the absence of GABA-A antagonists (Bjar-
nadottir et al., 2007; Chen et al., 2010b). The acute LTP-inhibiting
effect of Nrg1 was also observed when GABA-A receptor was
blocked (Kwon et al., 2005; Pitcher et al., 2011). This could sug-
gest the involvement of a GABA-A receptor-independent mech-
anism or differences in preparation or sensitivity to GABA-A
receptor blockade.36 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.In the secondmodel, Nrg1/Erbb4 signaling is thought to inhibit
Src kinase and thereby block the enhancement of NMDAR
function in pyramidal neurons that are injected with an Src-acti-
vating peptide (Pitcher et al., 2011) (Figure 6Cb). This study is
provocative because in most if not all occasions, Erbb activation
stimulates, but does not inhibit, Src or Src-like kinases (Kim
et al., 2005; Olayioye et al., 1999). In fact, Erbb4 has been shown
to interact with and thus activate Fyn, an Src-like kinase, in
response to Nrg1 stimulation (Bjarnadottir et al., 2007). More-
over, Nrg1/Erbb4 activates Src to phosphorylate kalirin-7 in in-
terneurons (Cahill et al., 2012). Therefore, it would be necessary
to know whether Nrg1-mediated blockade of NMDAR activity
enhancement requires Erbb4 in pyramidal neurons or interneu-
rons. If Erbb4 in interneurons is required, Src inhibition by Nrg1
may result from a circuitry event, i.e., GABA release from inter-
neurons (Figure 6Cb).
A third model implicates dopamine and D4 dopamine receptor
(D4R) in regulation of LTP (Figure 6Cc). Nrg1-mediated reversal
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or genetic deletion of D4R (Kwon et al., 2008). D4R belongs to
inhibitory D2-like dopamine receptor (Kebabian and Calne,
1979) and is expressed in not only pyramidal and GABAergic
interneurons, but also dopamine neuron axon terminals as well
(Noaı´n et al., 2006; Svingos et al., 2000). Postsynaptic D4R sup-
presses firing and excitability of pyramidal neurons (Rubinstein
et al., 2001); D4R activation augments the inactivation of synap-
tic NMDAR-mediated currents during LTP induction (Herwerth
et al., 2012). DA released by Nrg1 may inhibit LTP through D4R
in pyramidal neurons. This mechanism would not explain why
DA selectively activates D4R to suppress LTP but not D1-type
receptors that promote LTP (Frey et al., 1991; Huang and Kan-
del, 1995; Lisman and Grace, 2005; Otmakhova and Lisman,
1996). Future work is needed to determine whether Erbb4 is
necessary (and in what neurons) for induced dopamine release
and to determine whether D4R regulates dopamine release in
the hippocampus. A recent study indicates that D4R and
Erbb4 immunoreactivity overlap in a subset of PV+ interneurons
in the CA3 region (Andersson et al., 2012). Because dopamine
can promote GABA release (Harsing and Zigmond, 1997), D4R
may regulate LTP by boosting the function of PV+ GABAergic
neurons.
At the level of cortical-amygdala neural circuits, high-fre-
quency electrical stimulation of cortical inputs and TBS together
with nicotine exposure elicits LTP. This plasticity is impaired in
Nrg1 Type III heterozygous mice (Jiang et al., 2013). Here Nrg1
Type III is believed to target nicotinc a7 AChR to the presynaptic
terminal in cortical projection neurons (Hancock et al., 2008;
Zhong et al., 2008) and thus modulate excitatory plasticity at
cortical-amygdala synapses (Chen et al., 2008; Jiang et al.,
2013) (Figure 6Cd). In slices, the addition of soluble Erbb4-
ECD partially rescues LTP deficits, although it is unclear whether
the backward signaling is via interaction with Erbb4 on interneu-
rons or through some other mechanism or both.
Susceptibility Genes for Schizophrenia, Bipolar
Disorder, and Depression
Given the broad-range functions of Nrg/Erbb signaling networks
in key neural circuits in the brain, both during development and
in the adult, it can be assumed that Nrgs and Erbbs may also
contribute to neuropsychiatric diseases. Indeed, many NRGs
and ERBBs have been suggested to play a role in schizophrenia
(SZ) and other psychiatric disorders, including bipolar disorder
andmajor depression. In this section, wewill review the evidence
in support of this link. SZ is a ‘‘complex’’ disease with 80% her-
itability but, except for DISC1 in one pedigree, virtually no SZ
‘‘disease gene’’ shows Mendelian genetics, high penetrance,
or, in association studies, major odd ratios. Identification of a
locus on chromosome 8p21-p22 by genetic linkage and sub-
sequent fine mapping and haplotype-association analysis in
schizophrenic patients from Iceland led to the identification of
NRG1 as a candidate gene (Stefansson et al., 2002). Indepen-
dently, a study of Chinese Han SZ family trios revealed additional
SZ-associated SNPs on NRG1 (Yang et al., 2003). The genetic
association between NRG1 and SZ has been supported by
most but not all studies and meta-analyses in various popula-
tions (Li et al., 2006; Munafo` et al., 2006; Norton et al., 2006; Pet-ryshen et al., 2005), including recent genome-wide association
studies (GWASs) (Agim et al., 2013; Athanasiu et al., 2010; Shi
et al., 2009; Sullivan et al., 2008; see also Mei and Xiong,
2008). The human NRG1 gene is very large, spanning 1,125 kb
and harboring 23,094 SNPs,40 of which have been associated
with SZ so far. Most of these SNPs are intronic or in the 50 or 30
noncoding regions, except a few in exons (Figure 7). Increas-
ingly, ‘‘phenotype-based genetic association studies’’ (PGASs)
have provided biological and pathophysiological insight into
SZ ‘‘risk’’ genes (Ehrenreich and Nave, 2014), including NRG1.
In SZ patients, intronic SNPs, including those in the original
Icelandic ‘‘at risk’’ haplotype (in particular, SNP8NRG221533
and SNP8NRG243177) have been associated with reduced pre-
pulse inhibition (PPI), a measure of inhibitory sensorimotor
gating, and altered activity of frontal and temporal lobes, higher
risk for development of psychotic symptoms, and reduction in
premorbid IQ (Hall et al., 2006; Hong et al., 2008; Roussos
et al., 2011). Individuals who carry the SNP8NRG243177 (T/T)
genotype develop psychosis or express more unusual thoughts
during conflict-related interactions, suggesting that this SNP
is related to the onset of positive symptoms (Ke´ri et al., 2009;
Papiol et al., 2011). In healthy subjects, SNP8NRG221533 is
associated with decreased verbal fluency (Kircher et al., 2009;
Schmechtig et al., 2010), whereas SNP8NRG243177 relates to
reduced spatial working memory capacity (Kattoulas et al.,
2011). Interestingly, compared to other SZ patients, carriers of
both SNPs have been associated with increased brain activity,
better creativity, or intellectual achievement (Ke´ri, 2009; Krug
et al., 2008, 2010). Moreover, both SNPs have been associated
with a reduced volume of white and gray matter or increased
lateral ventricle volume in minimally medicated patients experi-
encing first episode of SZ (Barnes et al., 2012; Cannon et al.,
2012; Mata et al., 2010). Similarly, the SZ risk allele ‘‘C’’ of
SNP8NRG221533 is associated with decreased fractional
anisotropy (a measure of white matter integrity) in subcortical
white matter of the frontal lobe (Winterer et al., 2008) and
SNP8NRG243177 relates to reduced structural connectivity in
the internal capsule (McIntosh et al., 2008). These results are
compatible with the idea that NRG1 SNPs contribute to the
risk for SZ, in part, by affecting some aspect of human myelina-
tion that could not be modeled in Nrg1 mutant mice (Brinkmann
et al., 2008).
Because the SNPs of the Icelandic haplotype are intronic and
reside in the NRG1 50 region, it is plausible that they affect gene
expression by transcriptional or epigenetic modifications.
NRG1a and Type I in the brain or Ig-NRG1 in serum were re-
ported to be lower in SZ patients (Bertram et al., 2007; Parlapani
et al., 2010; Shibuya et al., 2010). However, there are more
studies reporting increased mRNA levels of NRG1 Type I, II,
and IV in the PFC and/or hippocampus of autopsy material
from SZ patients (Hashimoto et al., 2004; Law et al., 2006; Parla-
pani et al., 2010; Weickert et al., 2012) as well as in neurons
derived from induced pluripotent stem cells of SZ patients (Bren-
nand and Gage, 2012). Increases in Type I and IV mRNA relate
to SNP8NRG221132 and SNP8NRG243177, respectively (Law
et al., 2006;Moon et al., 2011). The picture for Type III expression
is less clear. In one study, an SNP in the NRG1 50 core promoter
region (rs7014762) was associated with SZ and significantlyNeuron 83, July 2, 2014 ª2014 Elsevier Inc. 37
Figure 7. NRG1, NRG3, and ERBB4 SNPs and Association with Psychiatric Disorders
Chromosome location, size, and the total number of SNPs of NRG1, NRG3, and ERBB4 are described under each gene name. Each oval represents a case
study. Colors indicate intronic or exonic SNPs with or without functional association or SNPs associated with bipolar disorder. *, SNPs implicated by GWAS. For
Nrg1, 1, rs73235619/Snp8nrg221132; 2, rs35753505/SNP8NRG221533; 3, rs4623364/SNP8NRG222662; 4, rs62510682/SNP8NRG241930; 5, rs6994992/
SNP8NRG243177; 6, rs7014762; 7, SNP8NRG433E1006; 8, rs4316112; 9, rs3924999; 10, rs2439272; 11, rs10095694; 12, rs16879809; 13, rs10503929; and 14,
rs74942016. For Nrg3, 1, rs10748842. For ErbB4, 1, rs7598440; 2, rs1851196; and 3, rs3748962.
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Reviewpredicted reduced NRG1 Type III mRNA levels in a U.S. Cauca-
sian population (Nicodemus et al., 2009). In another, the Icelan-
dic haplotype was associated with increased Type III mRNA
expression in the PFC in an Australian cohort of SZ patients
(Weickert et al., 2012). NRG1 Type III transcripts amplified from
peripheral leukocytes are higher in SZ patients (Petryshen
et al., 2005). Importantly, the increase in NRG1 transcript and
protein levels in patients did not correlate with antipsychotics
treatment (Chong et al., 2008; Law et al., 2006; Weickert et al.,
2012), suggesting that the association is indeedwith the disorder
and not medication. Notice that NRG1 Type III mRNA is more
abundant than Type I and IV mRNAs in human brains (Liu
et al., 2011). At a global level, changes in absolute mRNA copy
number for Type I and IV in SZ patients are expected to be
smaller than those of Type III. However, the situation may be
different at the single-cell level or in a specific brain region. Abun-
dantly expressed isoforms (such as Type III) may be more resil-
ient in biological consequences to small expression changes.
In addition to higher NRG1 levels in postmortem PFC of SZ
patients, a marked increase was observed in NRG1-induced
phosphorylation of ERBB4 kinase (Hahn et al., 2006). This sug-
gests that NRG1 signaling activity is indeed increased in relevant
brain regions of schizophrenic patients.
Four NRG1 exonic SNPs are nonsynonymous.
SNP8NRG433E1006 changes Arg to Gly in the Type II-specific
N-terminal region, whereas rs3924999, rs10503929, and
rs74942016 affect amino acids in the Ig, stalk, and transmem-
brane domains, respectively, which are contained in many iso-
forms (Falls, 2003; Mei and Xiong, 2008). These changes have
been associated with reduced PPI or cognition deficits in SZ
patients or with schizotypal personality disorder (Hong et al.,38 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.2008; Lin et al., 2005; Roussos et al., 2011). Intriguingly,
rs10503929, which specifies a missense mutation (V321L) in
the C-terminal transmembrane domain (Walss-Bass et al.,
2006), impairs g-secretase cleavage of Nrg1 (Dejaegere et al.,
2008) and therefore perturbs Nrg1 Type III signaling via the intra-
cellular domain and Nrg1 ‘‘back signaling’’ (Chen et al., 2010a).
NRGs and ERBB kinases show considerable crosstalk within
this family of ligands and receptors. SZ-associated SNPs have
been identified not only in NRG1, but also in NRG2, NRG3, and
NRG6 as well as in all ERBB genes, i.e., EGFR, ERBB2,
ERBB3, and ERBB4 (Benzel et al., 2007; Li et al., 2009; Mei
and Xiong, 2008). ERBB3 was reported to be lower in postmor-
tem brain of SZ patients (Aston et al., 2004). Among them, NRG3
and ERBB4 have been better characterized. Fine mapping of
chromosome 10q22, an SZ susceptibility locus, led to the iden-
tification of three intronic SNPs in intron 1 of NRG3 that were
associated with delusion symptom severity in patients with SZ
of Ashkenazi Jewish decent (Chen et al., 2009). Association of
these SNPs with SZ was observed in a family-based study
(Kao et al., 2010). Subsequently, more than 20 SNPs in NRG3
have been identified by case control studies and studies of
rare copy-number variants (Meier et al., 2013; Wang et al.,
2008; Xu et al., 2009) (Figure 7). Some are significantly associ-
ated with psychotic symptoms and attention performance SZ
(Kao et al., 2010; Meier et al., 2013) or prefrontal cortical physi-
ology in working memory (Tost et al., 2014; Rasetti et al.,
2011), whereas others relate to better performance in the
‘‘degraded-stimulus continuous performance’’ task, suggesting
that NRG3 may regulate attention processes for perceptual
sensitivity and vigilance (Morar et al., 2011). A risk SNP that
lies within a DNA ultraconserved element strongly predicts
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and normal controls (Kao et al., 2010). In mice, Nrg3 overexpres-
sion in the prefrontal cortex and knockout increased and
decreased, respectively, impulsivity, a symptom of schizo-
phrenia (Loos et al., 2014).
Many ERBB4 SNPs have been associated with SZ in genetic
association (Lu et al., 2010; Nicodemus et al., 2006, 2010; Silber-
berg et al., 2006) and in GWAS (Agim et al., 2013; Shi et al., 2009)
(Figure 7). Partial deletion of the ErbB4 kinase domain in a
schizophrenic patient has been identified by genome-wide
copy number analysis (Walsh et al., 2008). However, ERBB4
transcript as well as protein is higher in the PFC of schizophrenic
patients (Chong et al., 2008; Law et al., 2007; Silberberg et al.,
2006; Joshi et al., 2014). Notably, the isoform with the extracel-
lular JMa domain (that contains a proteolytic site) and the CYT-1
domain (that contains the sole binding site for PI3K) is overex-
pressed in the postmortem dorsal lateral PFC (DLPFC) (Law
et al., 2007; Silberberg et al., 2006). This increase is associated
with the ERBB4 risk haplotype of three SNPs (rs7598440,
rs839523, and rs707284) (Law et al., 2007). Of particular interest
is rs7598440, which predicts cortical GABA concentration in
healthy subjects in a magnetic resonance spectroscope study
(Marenco et al., 2011) and GABA levels in cerebrospinal fluid
(CSF) (Luykx et al., 2012). The effect of ERBB4was independent
of GAD67 (also known as GAD1) SNPs previously shown to pre-
dict GABA levels in same cohort (Marenco et al., 2010). Elevated
ERBB4 mRNA is related to interneuron deficits in the PFC in SZ
patients (Joshi et al., 2014). Together, these results of SZ
patients suggest GABAergic pathway as a target of ERBB4 mu-
tation, in agreement with studies of mouse models that reveal
critical roles of ERBB4 in development and function of the
GABA circuitry (as discussed above). The ERBB4 risk haplotype
is associated with high levels of PIK3CD/p110d, another SZ risk
gene, and reduced Akt activity in brains and B lymphocytes of SZ
patients, suggesting a potentially affected downstream pathway
(Law et al., 2012). Recently, a novel 6 kb haplotype block of four
SNPs, located within intron 19 of the ERBB4 gene, has been
associated with SZ in a Caucasian population (Agim et al., 2013).
Significant gene-gene interaction was observed between
NRG1 and NRG2, NRG3, NRG6, or ERBB4, and also between
NRG2 and EGFR (Benzel et al., 2007; Li et al., 2009; Nicodemus
et al., 2010; So et al., 2010). Additionally, NRG and ERBB genes
and activity could interact with other SZ susceptibility genes
such as DISC1 and a7 ACHR (Mata et al., 2010; Mathew et al.,
2007; Seshadri et al., 2010) or genes involved in Alzheimer’s dis-
ease such as BACE1 (Marballi et al., 2012). Collectively, these
findings underscore a likely contribution of the NRG-ERBB
signaling at several levels to SZ etiology. It is plausible that these
gene mutations may play complementary or synergistic roles in
SZ pathogenesis.
Considering the many roles of NRG1 in neural development
and synaptic plasticity, it is perhaps not surprising that NRG1
and ERBB4 genes have been implicated also in other brain dis-
orders. NRG1 SNPs including those defining the original Icelan-
dic haplotype are associated with bipolar disorders and major
depressive disorder (Goes et al., 2009; Green et al., 2005; O’Do-
novan et al., 2008; Prata et al., 2009; Thomson et al., 2007;
Walker et al., 2010). Likewise, NRG3 has been suggested as acandidate gene for ADHD (Sonuga-Barke et al., 2008) and
Alzheimer’s disease (Wang et al., 2014), and rs6584400 confers
genetic susceptibility to cognitive deficits in bipolar disorder
(Meier et al., 2013). Whether NRG1 is associated with Alz-
heimer’s disease is controversial (Go et al., 2005; Middle et al.,
2010), perhaps awaiting better subphenotypes as readouts.
Both NRG1 and NRG3 genes have been identified as suscepti-
bility genes of Hirschsprung’s disease, a congenital disorder
characterized by absence of enteric ganglia in distal intestine
(Garcia-Barcelo et al., 2009; Yang et al., 2013a), but whether
this relates like other causes of this disease to Schwann cell
functions in the neural crest lineage is unclear. A de novo recip-
rocal translocation t(2;6)(q34;p25.3) (with breakpoint between
exons 1 and 2) in the ERBB4 gene was found in a patient with
early myoclonic encephalopathy and profound psychomotor
delay (Backx et al., 2009). There is no evidence yet for a link of
NRG1 to autism although impaired hippocampal LTP and
contextual fear memory deficits in mice modeling Angelman
syndrome, a disorder related to the autism spectrum, can be
reversed by ErbB inhibitors (Kaphzan et al., 2012). Recently,
NRG3 and ERBB4 SNPs have been associated with nicotine
dependence and with successful smoking cessation (Loukola
et al., 2014; Turner et al., 2013). This is intriguing because smok-
ing is more prevalent among schizophrenic patients than in the
general population.
Pathophysiology of Abnormal Nrg/ErbB Signaling
While several genetic studies have suggested a link between the
NRG/ERBB signaling network and brain disorders, the patho-
physiological mechanisms underlying these disease connec-
tions are only starting to be explored in animal models. Both
reduced and increased NRG or ERBB level and/or activity has
been associated with SZ in postmortem studies of human brains
(see above). In animal models, mice lacking one copy of the
Nrg1, Erbb2, Erbb3, or Erbb4 gene exhibit various behavioral
deficits including hyperactivity in open field and impairment in
PPI, latent inhibition, reduced fear conditioning, reduced work-
ing memory, and/or abnormal social behavior (Boucher et al.,
2007; Chen et al., 2008; Duffy et al., 2008; Ehrlichman et al.,
2009; Gerlai et al., 2000; Karl et al., 2007; Moy et al., 2009;
O’Tuathaigh et al., 2006, 2010; Rimer et al., 2005; Stefansson
et al., 2002). Likewise, mice missing Nrg1 processing enzymes
such asBACE1 or neuropsin showed relevant behavioral deficits
(Savonenko et al., 2008; Tamura et al., 2012). Moreover, muta-
tion of Erbb4 alone or together with Erbb2 leads to hyperactivity
and impairment in PPI, fear conditioning, and learning/memory
(Barros et al., 2009; Chen et al., 2010b; Golub et al., 2004; Shamir
et al., 2012; Stefansson et al., 2002). Noticeably, many of these
deficits are observed in mutant mice in which Erbb4 has been
specifically ablated in interneurons (Chen et al., 2010b; Del
Pino et al., 2013; Shamir et al., 2012; Wen et al., 2010), suggest-
ing that interneurons are the target of abnormal Nrg1 signaling.
In terms of increased Nrg1 signaling, transgenic mice overex-
pressing neuronal Nrg1 Type I exhibited hyperactivity, reduced
PPI, impaired working memory, contextual fear conditioning,
and social interaction (Deakin et al., 2009; Deakin et al., 2012;
Kato et al., 2010; Luo et al., 2013; Yin et al., 2013a). Importantly,
switching off Nrg1 expression in pyramidal neurons of adultNeuron 83, July 2, 2014 ª2014 Elsevier Inc. 39
Figure 8. Inverted U Curve Illustrating the Relationship between
NRG1/ERBB Level and Activity and Cognitive/Behavioral
Performance
y axis shows cognitive/behavioral performance; darker color indicates poorer
performance. x axis showsNRG1 and ERBB level and activity with 1 as normal.
Green shade indicates the optimal range.
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(Luo et al., 2013; Yin et al., 2013a). This provides compelling ev-
idence that high levels of Nrg1 are pathogenic and suggests that
effects of abnormal development can be overcome. Conversely,
increase of Nrg1 in adult mice appears to be sufficient to impair
glutamatergic transmission and behavior (Yin et al., 2013a; Agar-
wal et al., 2014). These observations suggest that overexpres-
sion-induced deficits require continuous Nrg1 abnormality in
adulthood and that schizophrenia patients might benefit from a
therapeutic adjustment of NRG1 signaling.
Theoretically, there are two different pathophysiological con-
sequences of NRG1/ERBB4 loss-of-function mutations. The
mutation may lead to a loss or reduction of physiological
NRG1/ERBB4 functions in neural development and synaptic
transmission. Alternatively (or in addition), the loss of function
may result in a homeostatic compensatory effect that by itself
perturbs normal brain functions. For example, lack of Erbb4 in
PV+ interneurons impairs the assembly and function of
GABAergic circuitry and, as a result, excitatory neurons in the
circuitry downregulate synapse number or function (Cooper
and Koleske, 2011; Del Pino et al., 2013; Yin et al., 2013b). How-
ever, effects of Erbb4 mutations on interneuron firing are incon-
sistent in the literature. Firing of interneurons was reportedly
increased in the hippocampus of Lhx6-Cre;Erbb4/ mice but
reduced in mPFC of Dlx6-Cre;Erbb4/ mice (Del Pino et al.,
2013; Yang et al., 2013b). This discrepancy may result from dif-
ferences in brain regions, Cre lines used, or recording conditions
(such as ramp stimulation intensity) and warrants further studies.
Nevertheless, Erbb4 deletion in interneurons alters cortical excit-
ability and oscillatory activity and disrupts synchrony across
cortical regions (Del Pino et al., 2013; Fazzari et al., 2010; Wen
et al., 2010).
Elevated levels or activity of NRG1 or ERBB4may augment the
physiological function of NRG1 signaling. On the other hand,
perhaps in addition, high levels of NRG1 or ERBB4may be path-
ogenic via distinct, unrelated mechanisms, some of which could
be cell autonomous. For example, elevated Erbb4 levels in-
crease the spine density in neonatal, organotypic hippocampal
slices (Li et al., 2007). LIM kinase 1 (Limk1) is recruited into syn-
aptosomes following overexpression of Nrg1 (Yin et al., 2013a).40 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.LIMK1 is among the 25 genes deleted in Williams syndrome
(Tassabehji et al., 1996), and the gene is duplicated in some pa-
tients with autism (Sanders et al., 2011) or SZ (Kirov et al., 2012).
Subcutaneous injection of Nrg1 into neonatal mice decreases
latent inhibition and PPI by promoting dopaminergic function
(Kato et al., 2011) and chronic treatment with Nrg1 impairs
long-term depression of hippocampal inhibitory synapses by
reducing 2-arachidonoylglycerol, a major endocannabinoid (Du
et al., 2013). Upon activation, Erbb4 recruits and activates PI3
kinase (Figure 1). PI3KCD/p110d, a catalytic subunit of PI3
kinase, is increased in the brain of SZ patients (Law et al.,
2012); and inhibition of p110d increases Akt activity, attenuates
behavioral effects of amphetamine, and reverses PPI deficits in
SZ animal models. Likewise, truncation Erbb4 mutants may
have dominant-negative effects, in addition to loss of function
(Chen et al., 2003; Roy et al., 2007).
Evidently, both Nrg1 heterogyzous mouse mutants and trans-
genic overexpressors exhibit synaptic dysfunctions and behav-
ioral deficits. This suggests a model in which there is an
‘‘optimal’’ range for NRG1/ERBB signaling in the brain (Bjarna-
dottir et al., 2007; Tamura et al., 2012). Thus, the level and activity
of NRG1 isoforms, ERBB kinases, and partners must be tightly
regulated to maintain normal synaptic function and behavior
(Figure 8) (Marı´n and Rico, 2013; Role and Talmage, 2007). Ac-
cording to this model, either too much or too little NRG1/ERRB
signaling is sufficient to impair neural development and synaptic
plasticity and may lead to hypofunction of glutamatergic or
GABAergic pathways, both of which are implicated in schizo-
phrenia (Lewis and Moghaddam, 2006; Tsai and Coyle, 2002).
Conclusion
TheNRG-ERBB signaling in the brain is highly unusual because a
small group of ligands (NRG1–NRG6) and receptor genes
(ERBB2–ERBB4) creates a vastly complex network of signaling
proteins with multiple expression domains and divergent
functions in the developing and adult nervous system. Not sur-
prisingly, genetic association studies are providing growing evi-
dence that NRG and ERBB genes are associated with complex
brain disorders, such as SZ, bipolar disorder, and depression.
Phenotype-based association studies (PGASs) are revealing
biological functions of NRGs and ERBBs and pathophysiological
mechanisms associated with mutations. Moreover, in vivo
mouse studies indicate that the Nrg-Erbb network plays a critical
role in circuit assembly, peripheral myelination, and homeostasis
of CNS synaptic functions. Mouse models that mimic either
increased or decreased levels of NRG1 (or ERBB4) in develop-
ment exhibit relevant behavioral deficits, suggesting altered
signaling intensity as a pathophysiological mechanism.
While NRG1/ERBB signaling in axon-glia interaction and
myelination appears straightforward, the role of these genes in
neuronal communication raises new questions. First, despite
the association of SNPs in NRG1 and ERBB4 with several brain
disorders, evidence is tangential that they are ‘‘causal’’ and little
is known about how these SNPs alter the expression of NRGs
and ERBBs in SZ patients. It is also unclear how they interact
with other SZ risk factors including environmental factors. Sec-
ond, almost all pro-Nrgs isoforms are transmembrane proteins
and, following a complex proteolytic cleavage, release soluble
Neuron
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duction is thought to be coregulated by neuronal activity. An
answer to this question would also contribute to a better under-
standing of cell-adhesion-like of NRGs and ERBBs. Third, inter-
neuron abnormality is thought to cause cognitive deficits in SZ
patients. Intriguingly, there is evidence that in the cortex,
ERBB4 is expressed specifically in interneurons and perhaps is
the only receptor tyrosine kinase with interneuron expression
preference. In particular, ERBB4 is expressed in PV+ cells that
control the output of projection neurons. Moreover, SNPs and
mRNA of ERBB4 are associated with GABA levels or interneuron
deficits. Indeed, cognitive function is impaired in mutant mice
that lack Erbb4 in PV+ cells. These observations suggest
ERBB4 as an important target of abnormal NRG signaling. In
addition to PV+ cells, Erbb4 is also detected in other interneu-
rons. Whether their function is regulated by Nrg signaling
remains unknown. Is ERBB4 a marker of a new group of inter-
neurons that are vulnerable in SZ pathology? Future studies
will be warranted to understand the function of these Erbb4+
interneurons and their circuitry. Finally, SZ-relevant behavioral
deficits in mice that overexpress Nrg1 could be ameliorated by
reducing Nrg1 levels. This suggests that patients with relevant
symptoms may benefit from therapeutic intervention aimed at
restoring NRG1 signaling to the optimal level. Being strategically
expressed in interneurons, ERBB4 may serve as an ideal target
for drug development. Such drugs could specifically renovate
GABAergic activity with fewer side effects.ACKNOWLEDGMENTS
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